Cancer Genetics, Inc. Announces 25th Contract Win to Provide Testing & Diagnostic Services for Combination Immuno-Oncology Clinical Trial
20 sept. 2017 09h21 HE
|
Cancer Genetics, Inc.
Nearly half of the 50+ Immuno-Oncology Clinical Trials that CGI is supporting are combination trials involving multiple oncology drugs. CGI expects enrollment of over 4,500 patients into these...
Cancer Genetics, Inc. Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City, September 10-12, 2017
08 sept. 2017 07h30 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (The Company and CGI), a leader in enabling precision medicine for oncology through molecular markers and...
Cancer Genetics, Inc. to Host Conference Call to Discuss Strategic and Business Rationale of vivoPharm Acquisition
16 août 2017 07h00 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J. and LOS ANGELES, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (The Company and CGI), a leader in enabling precision medicine for oncology through molecular...
Cancer Genetics Announces Transformative and Accretive Acquisition of vivoPharm, a Global Oncology & Immuno-Oncology Discovery Services Company
14 août 2017 17h01 HE
|
Cancer Genetics, Inc.
Acquisition Strengthens CGI’s Bench-to-Bedside Capabilities and Bolsters Growth with Global Customer Base of Biopharma PartnersExpands Discovery and Early Development Revenue Base with Highly...
Cancer Genetics, Inc. Announces Second Quarter 2017 Financial Results, Accretive Acquisition and Capital Raise
14 août 2017 16h56 HE
|
Cancer Genetics, Inc.
Second quarter revenue of $6.6 millionRecord biopharma demand in quarter with $7.1 million in new contract bookings for Biopharma ServicesClinical Services Revenue up 20% over Q2 2016 to $3.0...
Cancer Genetics to Hold Second Quarter 2017 Earnings Call on Monday, August 14th
07 août 2017 16h30 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced...
DIA Elects Cancer Genetics, Inc.’s John A. (Jay) Roberts as Chairman of DIA Board of Directors
03 août 2017 07h30 HE
|
Cancer Genetics, Inc.
DIA is a professional community and knowledge exchange network for global health care product developmentMr. Roberts, who is also the Chief Operating Officer and EVP of Finance at Cancer Genetics,...
Cancer Genetics, Inc. Acclaimed by Frost & Sullivan For North American Technology Innovation in Precision Oncology
27 juil. 2017 07h00 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J. and LOS ANGELES, July 27, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through...
Cancer Genetics, Inc. Launches FDA-Approved Universal Companion Diagnostic for Lung Cancer Leveraging Thermo Fisher's Next Generation Sequencing Panel Oncomine Dx Target Test
27 juin 2017 07h34 HE
|
Cancer Genetics, Inc.
CGI is one of the first laboratories in the nation to offer the 23 gene testCGI is working with both pharmaceutical partners and clinical cancer centers to drive usage and adoptionEliminates need for...
Cancer Genetics, Inc. to Present at the 7th Annual LD Micro Invitational
02 juin 2017 07h59 HE
|
Cancer Genetics, Inc.
LOS ANGELES, June 02, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and...